Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter M Haddad

Showing results (81-90 of 94) with videos related to

Pageof 10
Sort By:
Therapeutic Advances in Psychopharmacology|February 3, 2016
Nurses' perceptions of medication adherence in schizophrenia: results of the ADHES cross-sectional questionnaire surveyRobin Emsley, Koksal Alptekin, Jean-Michel Azorin, et al.
Patient Preference and Adherence|February 8, 2013
Psychiatrists' awareness of adherence to antipsychotic medication in patients with schizophrenia: results from a survey conducted across Europe, the Middle East, and AfricaJosé Manuel Olivares, Köksal Alptekin, Jean-Michel Azorin, et al.
Trials|January 8, 2015
A randomised double-blind placebo-controlled 12- week feasibility trial of methotrexate added to treatment as usual in early schizophrenia: study protocol for a randomised controlled trialImran B Chaudhry, Nusrat Husain, Raza ur Rahman, et al.
Therapeutic Advances in Psychopharmacology|July 7, 2018
Amisulpride augmentation of clozapine for treatment-refractory schizophrenia: a double-blind, placebo-controlled trialThomas R E Barnes, Verity Leeson, Carol Paton, et al.
Health Technology Assessment (Winchester, England)|September 5, 2017
Amisulpride augmentation in clozapine-unresponsive schizophrenia (AMICUS): a double-blind, placebo-controlled, randomised trial of clinical effectiveness and cost-effectivenessThomas Re Barnes, Verity C Leeson, Carol Paton, et al.
Vaccines|June 2, 2021
Prevalence and Potential Determinants of COVID-19 Vaccine Hesitancy and Resistance in Qatar: Results from a Nationally Representative Survey of Qatari Nationals and Migrants between December 2020 and January 2021Salma M Khaled, Catalina Petcu, Lina Bader, et al.
The Lancet. Psychiatry|April 2, 2018
Antipsychotic drugs versus cognitive behavioural therapy versus a combination of both in people with psychosis: a randomised controlled pilot and feasibility studyAnthony P Morrison, Heather Law, Lucy Carter, et al.
The Lancet. Psychiatry|January 5, 2016
Antidepressant augmentation with metyrapone for treatment-resistant depression (the ADD study): a double-blind, randomised, placebo-controlled trialR Hamish McAllister-Williams, Ian M Anderson, Andreas Finkelmeyer, et al.
Schizophrenia Research|August 3, 2019
Psychiatrists' perceptions of medication adherence among patients with schizophrenia: An international surveyShunya Kurokawa, Taishiro Kishimoto, Kuan-Pin Su, et al.
Scientific Reports|February 4, 2022
Abnormal corneal nerve morphology and brain volume in patients with schizophreniaGeorgios Ponirakis, Reem Ghandi, Amani Ahmed, et al.
Pageof 10

Showing results (81-90 of 94) with videos related to

Sort By:
Pageof 10
Therapeutic Advances in Psychopharmacology|February 3, 2016
Nurses' perceptions of medication adherence in schizophrenia: results of the ADHES cross-sectional questionnaire surveyRobin Emsley, Koksal Alptekin, Jean-Michel Azorin, et al.
Patient Preference and Adherence|February 8, 2013
Psychiatrists' awareness of adherence to antipsychotic medication in patients with schizophrenia: results from a survey conducted across Europe, the Middle East, and AfricaJosé Manuel Olivares, Köksal Alptekin, Jean-Michel Azorin, et al.
Trials|January 8, 2015
A randomised double-blind placebo-controlled 12- week feasibility trial of methotrexate added to treatment as usual in early schizophrenia: study protocol for a randomised controlled trialImran B Chaudhry, Nusrat Husain, Raza ur Rahman, et al.
Therapeutic Advances in Psychopharmacology|July 7, 2018
Amisulpride augmentation of clozapine for treatment-refractory schizophrenia: a double-blind, placebo-controlled trialThomas R E Barnes, Verity Leeson, Carol Paton, et al.
Health Technology Assessment (Winchester, England)|September 5, 2017
Amisulpride augmentation in clozapine-unresponsive schizophrenia (AMICUS): a double-blind, placebo-controlled, randomised trial of clinical effectiveness and cost-effectivenessThomas Re Barnes, Verity C Leeson, Carol Paton, et al.
Vaccines|June 2, 2021
Prevalence and Potential Determinants of COVID-19 Vaccine Hesitancy and Resistance in Qatar: Results from a Nationally Representative Survey of Qatari Nationals and Migrants between December 2020 and January 2021Salma M Khaled, Catalina Petcu, Lina Bader, et al.
The Lancet. Psychiatry|April 2, 2018
Antipsychotic drugs versus cognitive behavioural therapy versus a combination of both in people with psychosis: a randomised controlled pilot and feasibility studyAnthony P Morrison, Heather Law, Lucy Carter, et al.
The Lancet. Psychiatry|January 5, 2016
Antidepressant augmentation with metyrapone for treatment-resistant depression (the ADD study): a double-blind, randomised, placebo-controlled trialR Hamish McAllister-Williams, Ian M Anderson, Andreas Finkelmeyer, et al.
Schizophrenia Research|August 3, 2019
Psychiatrists' perceptions of medication adherence among patients with schizophrenia: An international surveyShunya Kurokawa, Taishiro Kishimoto, Kuan-Pin Su, et al.
Scientific Reports|February 4, 2022
Abnormal corneal nerve morphology and brain volume in patients with schizophreniaGeorgios Ponirakis, Reem Ghandi, Amani Ahmed, et al.
Pageof 10